Towards improved ethanol production from lignocellulosic biomass

Ethanol from biological feedstock has emerged as a promising alternative for the generation of energy from renewable sources in order to mitigate the damages caused by the gas emissions associated to the consumption of fossil fuels. In many countries, ethanol is already being produced at industrial scale from different biological raw materials. However, there are some technical issues related to this process that need to be addressed and one of the major problems is the high heat requirements which makes this process less competitive against well-established fuels. This work proposes an optimisation methodology based on a dynamic approach to improve the overall efficiency of the process by considering new configurations and designs that allow the reduction of operating costs, usage of utilities, the size of units, etc. The work initially provides an introduction to the concept of fuels and the current global scenario regarding their production and consumption. Next, a general review of biofuels is given, in particular the production of ethanol from corn stover and the different units involved in this process. Additionally, mathematical formulations of the different units in the process are presented including detailed kinetic models and dynamic mass and energy balances. These models are first validated and then used in the construction of an overall model of the entire process which so far has not been available in open literature. This thesis also presents the development of an empirical mathematical model of an organophilic membrane for ethanol removal from aqueous solutions to increase the separation rates of ethanol in the process. Finally, this works presents the optimisation of the ethanol production process considering the implementation of heat storage units to reduce the consumption of utilities such as steam and cooling water by reducing the Total Annualised Cost (TAC). The results obtained show that the implementation of heat integration in the process can achieve a reduction of 7 % in the TAC and 10 % in the total energy consumption. These results indicate that ethanol production from corn stover with the use of energy storage is a viable alternative for energy generation that can become part of the main market of the production of green technologies

Paths to equilibrium in non-conformal collisions

We extend our previous analysis of holographic heavy ion collisions in non-conformal theories. We provide a detailed description of our numerical code. We study collisions at different energies in gauge theories with different degrees of non-conformality. We compare four relaxation times: the hydrodynamization time (when hydrodynamics becomes applicable), the EoSization time (when the average pressure approaches its equilibrium value), the isotropization time (when the longitudinal and transverse pressures approach each other) and the condensate relaxation time (when the expectation value of a scalar operator approaches its equilibrium value). We find that these processes can occur in several different orderings. In particular, the condensate can remain far from equilibrium even long after the plasma has hydrodynamized and EoSized. We also explore the rapidity distribution of the energy density at hydrodynamization. This is far from boost-invariant and its width decreases as the non-conformality increases. Nevertheless, the velocity field at hydrodynamization is almost exactly boost-invariant regardless of the non-conformality. This result may be used to constrain the initialization of hydrodynamic fields in heavy ion collisions

Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis

Background The public health impact of the COVID-19 pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear. Methods Using a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care, we explore the public-health impact of different potential therapeutics, under a range of scenarios varying healthcare capacity, epidemic trajectories; and drug efficacy in the absence of supportive care. Results The impact of drugs like dexamethasone (delivered to the most critically-ill in hospital and whose therapeutic benefit is expected to depend on the availability of supportive care such as oxygen and mechanical ventilation) is likely to be limited in settings where healthcare capacity is lowest or where uncontrolled epidemics result in hospitals being overwhelmed. As such, it may avert 22% of deaths in high-income countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for different patient populations (those not in hospital, early in the course of infection) and types of benefit (reducing disease severity or infectiousness, preventing hospitalisation) could have much greater benefits, particularly in resource-poor settings facing large epidemics. Conclusions Advances in the treatment of COVID-19 to date have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics delivered earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency–Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research

Indirect interactions in the High Arctic

Peer reviewe

Paths to equilibrium in non-conformal collisions

We extend our previous analysis of holographic heavy ion collisions in non-conformal theories. We provide a detailed description of our numerical code. We study collisions at different energies in gauge theories with different degrees of non-conformality. We compare four relaxation times: the hydrodynamization time (when hydrodynamics becomes applicable), the EoSization time (when the average pressure approaches its equilibrium value), the isotropization time (when the longitudinal and transverse pressures approach each other) and the condensate relaxation time (when the expectation value of a scalar operator approaches its equilibrium value). We find that these processes can occur in several different orderings. In particular, the condensate can remain far from equilibrium even long after the plasma has hydrodynamized and EoSized. We also explore the rapidity distribution of the energy density at hydrodynamization. This is far from boost-invariant and its width decreases as the non-conformality increases. Nevertheless, the velocity field at hydrodynamization is almost exactly boost-invariant regardless of the non-conformality. This result may be used to constrain the initialization of hydrodynamic fields in heavy ion collisions

Thermodynamics, transport and relaxation in non-conformal theories

We study the equilibrium and near-equilibrium properties of a holographic five-dimensional model consisting of Einstein gravity coupled to a scalar field with a non-trivial potential. The dual four-dimensional gauge theory is not conformal and, at zero temperature, exhibits a renormalisation group flow between two different fixed points. We quantify the deviations from conformality both in terms of thermodynamic observables and in terms of the bulk viscosity of the theory. The ratio of bulk over shear viscosity violates Buchel’s bound. We study relaxation of small-amplitude, homogeneous perturbations by computing the quasi-normal modes of the system at zero spatial momentum. In this approximation we identify two different relaxation channels. At high temperatures, the different pressures first become approximately equal to one another, and subsequently this average pressure evolves towards the equilibrium value dictated by the equation of state. At low temperatures, the average pressure first evolves towards the equilibrium pressure, and only later the different pressures become approximately equal to one another

Structure of eEF3 and the mechanism of transfer RNA release from the E-site

Elongation factor eEF3 is an ATPase that, in addition to the two canonical factors eEF1A and eEF2, serves an essential function in the translation cycle of fungi. eEF3 is required for the binding of the aminoacyl-tRNA–eEF1A–GTP ternary complex to the ribosomal A-site and has been suggested to facilitate the clearance of deacyl-tRNA from the E-site. Here we present the crystal structure of Saccharomyces cerevisiae eEF3, showing that it consists of an amino-terminal HEAT repeat domain, followed by a four-helix bundle and two ABC-type ATPase domains, with a chromodomain inserted in ABC2. Moreover, we present the cryo-electron microscopy structure of the ATP-bound form of eEF3 in complex with the post-translocational-state 80S ribosome from yeast. eEF3 uses an entirely new factor binding site near the ribosomal E-site, with the chromodomain likely to stabilize the ribosomal L1 stalk in an open conformation, thus allowing tRNA release